Article
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
The Lancet. Oncology - 1 Jul 2026
Li Ziming, Hu Jie, Chen Jianhua, Yu Yan, Meng Xiangjiao, Dong Xiaorong, Hu Yanping, Ji Yinghua, Liu Haifeng, Wang Weibo, Ning Fangling, Zhang Zhihong, Liu Chunling, Zhang Zhiye, Wang Qiming, Zheng Wei, Wang Honghai, Qu Xiujuan, Chen Zhenming, Fan Shaonan, Zhang Xiaoqing, Lu Shun
Abstract excerpt
BACKGROUND: Although third-generation epidermal growth-factor receptor (EGFR)-tyrosine-kinase inhibitors (TKIs) are standard first-line therapies for patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC), their effectiveness is often limited by the emergence of drug resistance and subsequent disease progression. Given the previously established clinical efficacy and adverse event profile of...
Topics
Join the communities discussing this publication.